Tag: Chronic myeloid leukemia

In clinical trials, diarrhea has been identified as a very common side effect of imatinib, affecting a significant portion of patients undergoing treatment for cancers like Chronic Myeloid Leukemia (CML) and Gastrointestinal Stromal Tumors (GIST). This gastrointestinal issue, often ranging from mild to moderate, is a recognized consequence of the drug's mechanism of action.

While it can seem confusing, the short answer is yes: Imatinib is the active drug ingredient in the medication branded and sold as Gleevec. This relationship is common in the pharmaceutical world, where a single chemical compound is known by its official generic name and by one or more brand names.

Synribo (omacetaxine mepesuccinate) was permanently discontinued due to manufacturing issues, with remaining inventory expected to be exhausted in late 2023. This article explores the detailed reasons for its withdrawal and its place in cancer therapy.